← Home / LISATA THERAPEUTICS, INC. (LSTA)
Stock Analysis

LISATA THERAPEUTICS, INC. (LSTA)

LSTA
LSTA · Healthcare • Biotechnology
1.81 +1.12%
Track LSTA in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when LSTA price is:
52W Range Position
20%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-27 04:12 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and structural levels before acting.
⚖️
✓
Fundamentals
Weak / Negative / Pressured / Strong
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Current Resistance
Below Resistance
Risk Level
Elevated
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
1.81
↗
Break Above
No reliable confirmation level is currently available.
Not available
🎯
Next Objective
No defined objective is currently available for the primary technical setup.
Not available
×
Thesis Break
No setup-specific invalidation level is currently defined.
Not available
Recent Company Events
SEC VERIFIED
Latest material filings
AUG
4
◆
M&A
HIGH
LSTA merger or acquisition update
Costs Associated with Exit or Disposal Activities.
8-K Filing • SEC EDGAR
AUG
4
●
Management / Board
HIGH
LSTA board and management update
In connection with the reduction in workforce approved by the Board on August 3, 2026, effective as of August 3, 2026, the employment of Dr.
8-K Filing • SEC EDGAR
JUL
24
●
Material Agreement
HIGH
LSTA material agreement
Termination of a Material Definitive Agreement On July 24, 2026, Lisata Therapeutics, Inc.
8-K Filing • SEC EDGAR
What's Driving LSTA?
• No active technical setup
Momentum is Neutral. No qualified technical setup is currently active.
◆ Business quality is mixed
Revenue growth is weak. Profitability is negative. Cash generation is pressured. Balance-sheet quality is strong.
⚠️ Key risk remains
Below 1.81
Full Analysis Workspace
Technical Signal
No Active Technical Setup
•
No qualified technical setup is currently active.
RSI(14)
56.5
Price Chart
LSTA — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-08-26
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$15.7M
Company size
EV
$5.0M
Debt-adjusted value
P/S
156.8
Very high
P/B
1.9
Low book multiple
EV/Sales
49.8
Very high
EV/EBIT
-0.3
Not meaningful
P/FCF
-1.9
Not meaningful
Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Weak
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
0.00
↘ Weak
📈 Net Income
-2.93M
↘ Negative
🧮 EPS (Basic)
-0.32
↘ Negative
LISATA THERAPEUTICS, INC.
Healthcare • Biotechnology
You Might Also Like